US5602184A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Monoterpenes, sesquiterpenes and diterpenes as cancer therapy
Assignee: United States Department of Health and Human Services
•
Filing: 1993-03-03
•
Granted: 1997-02-11
•
Expires: 2013-03-03
Abstract
Abstract The invention provides methods of treating cancer including administering an effective amount of selected terpenes to a mammal having the cancer when the cancer is prostate cancer, colon cancer, astrocytoma, or sarcoma. The terpene is selected from the group consisting of a cyclic monoterpene, a noncyclic monoterpene, a noncyclic sesquiterpene and a noncyclic diterpene. The invention also provides a method of sensitizing a cancer to radiation including administering an effective amount of a terpene to a mammal having the cancer wherein the terpene is selected from the group noted above. Additionally, the invention provides methods of inhibiting the growth of cancer cells including applying an effective amount of a selected terpene to the cancer cells which are cells of prostate cancer, colon cancer, osteosarcoma, or glioblastoma.
Inventors
- 👤 Charles E. Myers
- 👤 Jane Trepel
- 👤 Edward Sausville
- 👤 Dvorit Samid
- 👤 Alexandra Miller
- 👤 Gregory Curt
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 00:30
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/01; A61K31/015; A61K31/045; A61K41/00; A61K41/0038
Claims Analysis
Total Claims: 24
Claim 1
Independent Claim
81 words
A method of treating prostate cancer comprising administering an effective amount of terpene to a mammal having prostate cancer, said terpene selected from the group consisting of a diterpene of the formula ##STR4## and a sesquiterpene of the formula ##STR5## wherein R 1 , R 2 , R 3 , R 4 , and R 5 are selected from the group consisting of a hydrogen and a lower alkyl group, and wherein the terpene contains at least one site of unsaturation.
Claim 2
Independent Claim
81 words
A method of treating prostate cancer comprising administering an effective amount of terpene to a mammal having prostate cancer, said terpene selected from the group consisting of a diterpene of the formula ##STR4## and a sesquiterpene of the formula ##STR5## wherein R 1 , R 2 , R 3 , R 4 , and R 5 are selected from the group consisting of a hydrogen and a lower alkyl group, and wherein the terpene contains at least one site of unsaturation.
Claim 3
Dependent Claim
10 words
The method of claim 1 wherein the cancer is metastatic.
Claim 4
Dependent Claim
13 words
The method of claim 1 wherein the administration is either oral or topical.
Claim 5
Dependent Claim
11 words
The method of claim 1 wherein the mammal is a human.
Claim 6
Dependent Claim
23 words
The method of claim 4 wherein the effective amount is selected from a range of from about 9 mg/kg/day to about 0.10 gm/kg/day.
Claim 7
Dependent Claim
22 words
The method of claim 5 wherein the effective amount is selected from a range of from about 0.02 to about 1.15 mg/kg/day.
Claim 8
Dependent Claim
13 words
The method of claim 1 wherein the diterpene is either phytol or geranylgeraniol.
Claim 9
Dependent Claim
10 words
The method of claim 1 wherein the terpene is phytol.
Claim 10
Independent Claim
84 words
A method of sensitizing prostate cancer to radiation comprising administering an effective amount of a terpene to a mammal having the cancer, said terpene selected from the group consisting of a diterpene of the formula ##STR6## and a sesquiterpene of the formula ##STR7## wherein R 1 , R 2 , R 3 , R 4 , and R 5 are selected from the group consisting of a hydrogen and a lower alkyl group, and wherein the terpene contains at least one site of unsaturation.
Claim 11
Independent Claim
84 words
A method of sensitizing prostate cancer to radiation comprising administering an effective amount of a terpene to a mammal having the cancer, said terpene selected from the group consisting of a diterpene of the formula ##STR6## and a sesquiterpene of the formula ##STR7## wherein R 1 , R 2 , R 3 , R 4 , and R 5 are selected from the group consisting of a hydrogen and a lower alkyl group, and wherein the terpene contains at least one site of unsaturation.
Claim 12
Dependent Claim
10 words
The method of claim 9 wherein the cancer is metastatic.
Claim 13
Independent Claim
34 words
A method of inhibiting the growth of prostate cancer cells comprising applying an effective amount of a terpene to the cancer cells, said terpene selected from a group consisting of farnesol, phytol and geranylgeraniol.
Claim 14
Independent Claim
34 words
A method of inhibiting the growth of prostate cancer cells comprising applying an effective amount of a terpene to the cancer cells, said terpene selected from a group consisting of farnesol, phytol and geranylgeraniol.
Claim 15
Dependent Claim
10 words
The method of claim 11 wherein the application is indirect.
Claim 16
Dependent Claim
19 words
The method of claim 12 wherein the cancer cells are located in a mammal and the application is oral.
Claim 17
Dependent Claim
11 words
The method of claim 13 wherein the mammal is a human.
Claim 18
Dependent Claim
23 words
The method of claim 14 wherein the effective amount is selected from a range of from about 9 mg/kg/day to about 0.10 gm/kg/day.
Claim 19
Dependent Claim
22 words
The method of claim 15 wherein the effective amount is selected from a range of from about 0.02 to about 0.15 gm/kg/day.
Claim 20
Dependent Claim
13 words
The method of claim 13 wherein the application is made once a day.
Claim 21
Independent Claim
19 words
A method of treating prostate cancer comprising administering an effective amount of geranylgeraniol to a mammal having the cancer.
Claim 22
Independent Claim
19 words
A method of treating prostate cancer comprising administering an effective amount of geranylgeraniol to a mammal having the cancer.
Claim 23
Independent Claim
22 words
A method of inhibiting the growth of prostate cancer cells comprising applying an effective amount of geranylgeraniol to the prostate cancer cells.
Claim 24
Independent Claim
22 words
A method of inhibiting the growth of prostate cancer cells comprising applying an effective amount of geranylgeraniol to the prostate cancer cells.
References Cited (Backward Citations)
EP0285302A1
Cited
JPH02270544A
Cited
EP0393973A1
Cited
JPH0398562A
Cited
US5243094A
Cited
WO1992018465A2
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2000-02-11 | 2000-08-12 | 2001-02-11 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2004-02-11 | 2004-08-12 | 2005-02-11 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2008-02-11 | 2008-08-12 | 2009-02-11 | $7700.00 | Window Closed / Lapsed |